Synthetic biology can benefit all of us, an expert explains – World Economic Forum

The bioeconomy covers all sectors and systems that rely on biological resources (animals, plants, microorganisms, and derived biomass, including organic waste) as well as their functions and principles. It includes and interlinks economic and industrial sectors such as food, health, chemicals, materials, energy and services that use biological resources and processes.

It is anticipated that the world will face increased competition for limited and finite natural resources given a growing population, increasing pressure on our food and health systems, and climate change and associated environmental degradation decimating our primary production systems.

Synthetic biology is an emerging field which applies engineering principles to the design and modification of living systems, thus underpinning and accelerating technological advances with clear potential to provide impact at scale to the global economy. Manufacturers are turning towards this method to efficiently produce high performance, sustainable products.

A recent McKinsey report anticipates applications from this bio revolution could have a direct global impact of up to $4 trillion per year over the next 10-20 years, enabling production of 60% physical inputs to the global economy, and addressing 45% of the worlds current disease burden. However, for synthetic biology applications to reach their full potential, its critical to ensure that access and development of knowledge in this sector, along with the relevant research tools, are distributed in low resource contexts. This can help to avoid the technology being centered solely in advanced, resource rich economies and widening inequalities in the global bioeconomy.

Dr. Jenny Molloy, Senior Research Associate at the Department of Chemical Engineering and Biotechnology, University of Cambridge, studies the role and impact of open approaches to intellectual property for a sustainable and equitable bioeconomy.

Her work focuses on better understanding problems facing researchers accessing biological research tools in low resource contexts, particularly Latin America and Africa. Her team develops innovative technologies for local, distributed manufacturing of enzymes to improve access and build capacity for biological research. The broader aim of her research is to contextualize open source approaches to biotechnology within current narratives of innovation and the bioeconomy policy agenda. She is also a member of the World Economic Forum Global Future Council on Synthetic Biology.

We discussed new developments, challenges, and her ideal scenario for the bioeconomy policy agenda for the next 10 years. Here's what she said:

Realizing that the current system of how we fund, reward, publish and disseminate science, and how we balance public and private interests in technology is quite recent and could be changed.

Originally, I worked on advocacy for open data and open science (which fortunately is now much more mainstream within research culture), and then my introduction specifically to bioeconomy policies came when I worked on genetic modification of dengue mosquitoes for my doctorate. This put me right at the intersection of global health, synthetic biology, and the bioeconomy in a field nested in a complex tangle of ethics, regulation, responsible innovation, and public opinion.

At the same time, I was contributing to projects on open science for development and getting more interested in how to make access to science, innovation, and its benefits truly global. Everything started pointing to the imperative of working to ensure that we collectively build a global bioeconomy that is equitable and economically and environmentally sustainable.

Id say the ability to de novo synthesise DNA at scale and precisely edit it. When I was trying to genetically engineer mosquitoes, constructing DNA modules was laborious and it was really a roll of the dice as to where in the genome that DNA would end up. Having more affordable ways to write as well as read DNA with increased elegance, precision editing of CRISPR has enabled exciting advances to address so many global challenges: from drug discovery to crop improvement.

That is why I find enabling tools and technologies so exciting: they underpin innovation and users will deliver applications that the original developers didnt dream about. A lot of my work focuses on how to ensure that these developments reach all scientists and not only those in high income countries.

I would say the perception and narrative that is strongly embedded in biotechnology at all levels that open source means uncommercialisable.

Unfortunately, this leads to an unwillingness to creatively explore openness as one possibility within a whole range of Intellectual Property (IP) strategies. I wish people knew to ask, What impact do I want to achieve in the world and to what extent can protecting or openly sharing this technology get me there?. Sometimes, youll land back on patenting everything because the promise of a monopoly is required to unlock sufficiently risk tolerant investment. That is OK!

However, the answer is likely more nuanced when your goal is also environmental or social impact or where you have a user community that could contribute back significant innovations or for many other reasons. Teslas patent pledge in 2014 was likely partially because their success depends on public and private investment in infrastructure like charging stations, so while sharing their technology might allow competitors to get to market faster, that could increase the number of electric cars on the road and the interests of electric car drivers and industry. All this nuance gets missed if you dont ask the question.

One of the best sources of knowledge in biotechnology is, perhaps somewhat ironically, published patents! Developing and emerging economies have immense freedom to apply this knowledge commercially as very few biotech patents have been filed in the Global South while many more have expired and entered the public domain.

However, there are major challenges to making that knowledge used and useful, including having enough people skilled in the art and providing an enabling environment - well equipped labs, reliable supply chains, responsive regulation and funding. Open source approaches play an important role here because beyond open licensing they also encourage collaborative development and sharing of know how, which is essential to overcome barriers to building capacity and innovation.

The application of precision medicine to save and improve lives relies on good-quality, easily-accessible data on everything from our DNA to lifestyle and environmental factors. The opposite to a one-size-fits-all healthcare system, it has vast, untapped potential to transform the treatment and prediction of rare diseasesand disease in general.

But there is no global governance framework for such data and no common data portal. This is a problem that contributes to the premature deaths of hundreds of millions of rare-disease patients worldwide.

The World Economic Forums Breaking Barriers to Health Data Governance initiative is focused on creating, testing and growing a framework to support effective and responsible access across borders to sensitive health data for the treatment and diagnosis of rare diseases.

The data will be shared via a federated data system: a decentralized approach that allows different institutions to access each others data without that data ever leaving the organization it originated from. This is done via an application programming interface and strikes a balance between simply pooling data (posing security concerns) and limiting access completely.

The project is a collaboration between entities in the UK (Genomics England), Australia (Australian Genomics Health Alliance), Canada (Genomics4RD), and the US (Intermountain Healthcare).

For example, basic laboratory equipment like incubators are typically no longer protected by IP but you will rarely find full assembly and repair instructions online: open hardware projects provide this and bring together communities of developers and manufacturers to enable local manufacturing. Access to enzymes is an almost ubiquitous challenge in the Global South and while many useful enzymes are now in the public domain, it can be time consuming to find the DNA and protocols to express them.

Open toolkits like the Research in Diagnostics DNA Collection designed by my lab and many collaborators and distributed through the Free Genes project at Stanford provides a ready to go solution that with the correct manufacturing practices, quality management systems and regulatory approvals could also be used for diagnostics kits. Local manufacturing of molecular diagnostics is a possibility we are exploring with collaborators in Cameroon and Ghana, for example through the AfriDx project funded by EDCTP.

A great example of an open project that has already had a direct impact on scientific progress is the Structural Genomics Consortium, a public-private-partnership which has openly released data, materials and research tools for drug discovery against medically relevant human protein structures to academia and industry for around 20 years, resulting in thousands of collaborations and scientific papers and over 1500 protein structures entering the public domain. The leaders of the consortium continue to push the model further, for example launching pharma companies that aim to apply an open approach to drug discovery for rare childhood cancers.

Realizing that the current system of how we fund, reward, publish and disseminate science and how we balance public and private interests in technology is quite recent and could be changed.

My ideal scenario is that the global bioeconomy policy agenda is truly global, so that over the next 10 years countries in the Global South, that host so much of the biodiversity that is fuelling the bioeconomy, are able to shape that agenda, to level up innovation capacities, and to benefit from the bioeconomy on their own terms.

My advice to global leaders and policymakers is to ensure that all countries get a seat at the table and focus on building out more than local or regional policies but also systems for international governance that can adapt to the extraordinary pace of technical and social change in the bioeconomy.

The Global Future Council on Synthetic Biology has focused a lot of our attention on how to embed the values of sustainability, equity, humility and solidarity into the future bioeconomy policy agenda, providing a compass rather than a map, because we think this is important to ensure that synthetic biology is being harnessed to create a world in which we want to live.

Written by

Abhinav Chugh, Acting Content and Partnerships Lead, World Economic Forum

The views expressed in this article are those of the author alone and not the World Economic Forum.

Read the rest here:

Synthetic biology can benefit all of us, an expert explains - World Economic Forum

FSSAI Seeks Public Input on the Regulation of Genetically Modified Foods – Krishi Jagran

Vegetables

The Food Safety and Standards Authority of India (FSSAI) has requested public feedback on a draft regulation governing the manufacture, storage, distribution, sale, and import of any food or food ingredient derived from genetically modified organisms (GMOs).

In its draft notification, FSSAI also proposed that all food products containing one percent or more genetically engineered ingredients be labeled Contains GMO/Ingredients derived from GMO.

The regulation applies to GMOs, also known as genetically engineered organisms (GEOs) or living modified organisms (LMOs), that are intended for direct consumption or processing. It also applies to genetically modified ingredients derived from but not containing LMOs, GEOs, or GMOs in processed foods.

The draft notification states that prior FSSAI approval is required for the manufacture, storage, distribution, sale, and import of any food or food ingredient derived from GMOs.

Even after receiving prior approval from the biotech regulator Genetic Engineering Appraisal Committee (GEAC) under the Environment Ministry, FSSAI approval is required.

The FSSAI may approve or reject the application based on the safety assessment of the food article and food ingredient of a processing aid.

Following FSSAI approval, food business operators must apply for a license in accordance with the Food Safety and Standards (Licensing and Registration of Food Businesses) Regulations, 2011.

Post-approval, the FSSAI stated that if a food business operator has reason to believe that GMOs or GEOs pose a health risk, he should immediately "suspend" the manufacture, import, sale, or distribution of such food items and take steps to recall them.

Once a GMO, GEO, or LMO with a 'unique identification code' (provided by the Biosafety Clearing-House, Organization for Economic Cooperation and Development, etc.) is approved by FSSAI, no other food business operator will need to apply for approval, according to the draught notification.

It also stated that approval will not be required if it is used as an ingredient in any product. Furthermore, the FSSAI stated that any food laboratory with a designated GM food testing area may be designated for GM food testing.

The FSSAI has given the public 60 days from the date of the draught notification's release on November 15 to submit any objections or suggestions.

Excerpt from:

FSSAI Seeks Public Input on the Regulation of Genetically Modified Foods - Krishi Jagran

Animal Genetics Market Worth ($7705.23 Mn by 2027) by (6.3% CAGR) with Impact of Coronavirus Outbreak and Global Analysis & Forecast by The…

PUNE, India, Nov. 25, 2021 /PRNewswire/ -- According to The Insight Partners study on "Animal Genetics Market to 2027 Global Analysis and Forecast by Animal Genetic Material, Genetic Material and Service" the animal genetics market was valued at US$ 4,778.67 million in 2019 and is projected to reach US$ 7,705.23 million by 2027; it is expected to grow at a CAGR of 6.3% during 20192027. The growth of the market is attributed to the growing preference for animal derived proteins supplements and food products and rising adoption of progressive genetic practices such as artificial insemination (AI) and embryo transfer. However, limited number of skilled professionals in veterinary research and stringent government regulations for animal genetics is expected to hinder the market growth.

The North American region holds the largest market share of this market and is expected to grow in forecasted years. The growth in North America is characterized by the presence of new market players, various product launches and increasing government initiatives.

Get Exclusive Sample Pages of Animal Genetics Market - COVID-19 Impact and Global Analysis with Strategic Insights at https://www.theinsightpartners.com/sample/TIPRE00003517/

Likewise, Mexico is likely to offer attractive business opportunities for livestock genetics. Over the last decades, Mexico's beef, pork, and dairy productions have undergone valuable developments. Mexican generators in the expanding livestock intensive systems are frequently using modern genetic improvement technologies such as artificial insemination and embryo transfers.

In North America, the US is the largest market for animal genetics market. Livestock groups provide consumers with different products and services, including meat, milk, eggs, fiber, and draught power. The genetic variation within livestock communities produces the raw material for evolving through natural selection in answer to changing conditions and human-managed genetic improvement plans. As per the Food and Agriculture Organization (FAO), animal genetics is one of the livestock development support. It is a wide field, ranging from characterization to conservation to genetic development. According to the National Institute of Food and Agriculture (NIFA), there have been dramatic improvements in animal production yields and efficiencies. Therefore, the ever-increasing demand for dietary protein in the United States has been observed. These demands are achieved by one the best Animal breeding is one strategy by which these improvements may be performed. NIFA, with the help of scientists from universities and research organizations and food animal industries, provides national leadership and funding opportunities to conduct basic, applied, and integrated research to increase knowledge of animal genetics and genomics.

The COVID-19 outbreak has disturbed various trades and businesses across the world. The incidence of corona virus or COVID 19 has not yet been registered the animals. Also, there is no evidence that companion animals are the prime source of the spreading epidemic in humans. However, various studies have been conducted to check the spread of disease from animals to humans. In many cases, zoonotic diseases were found in humans due to interaction with animals. Therefore, government bodies are taking more precautions and safety measures to prevent the spread of corona virus in the animals. The measures are widely carried out for companion animals as they frequently come in contact with their owners. Also, it is essential to report the cases to a veterinary authority. For instance, in the region, to report the cases of detection of COVID-19 is done to OIE through WAHIS, in accordance with the OIE Terrestrial Animal Health Code as an emerging disease.

The OIE is actively working by providing assistance to research for their on-going research and other implications of COVID-19 for animal health and veterinary public health. The assistance is also providing risk assessment, risk management, and risk communication. Also, the OIE has put in place an Incident Coordination System to coordinate these activities. In addition, OIE is also working with the Wildlife Working Group and other partners to develop a long-term work program. The aims are to provide better understandings, dynamics, and risks around wildlife trade and consumption. Also, it aims to develop strategies to reduce the risk of future spillover events.

Download the Latest COVID-19 Analysis on Animal Genetics Market Growth Research Report at https://www.theinsightpartners.com/covid-analysis-sample/TIPRE00003517/

Additionally, various product and service launches have been initiated, which is helping the US market to grow. For instance, The Veterinary Genetics Laboratory (VGL) at the UC Davis School of Veterinary Medicine has launched an updated and advanced website along with several new tests for veterinary community. As the VGL is one of the foremost genetic testing laboratories in the world, the new site and tests will bring yet another level of global impact to the top-ranked veterinary school. Thus, the consistent support for combating addiction in the country undertaken by various organizations likely to augment the growth of animal genetics market during the forecast years.

The Asia Pacific region is expected to be the fastest-growing region among all other regions. The growth of the market in the region is majorly due to countries like China, India and Japan, which drives the major consumption of animal derived products. Moreover, growing preference for animal derived proteins supplements and food products, and rising adoption of progressive genetic practices such as artificial insemination (AI) and embryo transfer are also likely to contribute to market growth. On the other hand, significant investment by government in various breeding programs is supporting the growth of market. For instance, the central and local governments have invested more than RMB 5 billion to build breeding or multiplier farms and conservation farms for breed improvement programs and the building of centers for testing the quality of breeding stock, semen, and embryos.

Based on product, the animal genetics market is segmented poultry, porcine, bovine, canine, and others. The porcine segment accounted for more than 35.84% of the market share in 2019. In terms of genetic material, the animal genetics market is segmented into semen, and embryo. The embryo segment held the largest share of the market in 2019. In terms of service, the animal genetics market is segmented into DNA typing, genetic trait tests, genetic disease tests, and others.The DNA typing segment held the largest share of the market in 2019.

Rising Adoption of Progressive Genetic Practices Such as Artificial Insemination (AI) and Embryo Transfer in Animal Genetics Market:

Growing focus on developing superior animal breeds using genetic engineering to obtain high reproduction rates for large-scale production of modified breeds is expected to drive animal genetics market during the forecast period. Animal genetics emphasizes the inheritance and genetic variations in wild and domestic animals. This science is used at a commercial level for services such as testing genetic disorders, screening genetic traits, and typing DNA. For identifying genetic hybridizations, animal genetics uses various genetic practices, such as artificial insemination, embryo transfer, and cytological studies. Moreover, artificial insemination (AI) can reduce various risks involved in animal breeding and disease transmission. It is found that female offspring cattle born through artificial insemination yield more milk than normal offspring. Additionally, the use of antibiotic-containing semen extensors is effective in preventing bacterial infectious diseases. Therefore, the entire AI process is considered hygienic than natural mating.

The market players are focusing on partnerships, collaboration, and acquisitions to develop genetically modified breeds and maintain their market share. For instance, in August 2020, Cogent and AB Europe collaborated to launch a novel sexed semen service for sheep producers in the UK. In May 2018, Recombinetics entered into partnership agreement with SEMEX for the implementation of a precision breeding program, which is expected to improve animal health and well-being through hornless dairy cattle genetics. According to the Brazilian Association of Artificial Insemination, the number of commercialized doses of semen increased from 7 million in 2003 to ~14 million in 2017. Thus, rising adoption of genetic practices will support the market growth in coming years.

Inquire before Buying (Animal Genetics Market Research): https://www.theinsightpartners.com/inquiry/TIPRE00003517/

Market: Segmental Overview

In terms of product, porcine segment is anticipated to register the highest CAGR during the forecast period. Growing production of porcine and increase in pork consumption is likely to favor the growth of the market. Pork is the most consumed meat across the globe. In the US, pork production generates $23.4 billion output per year. Additionally, 26% that is around 2.2 million metric tons of pork and its products are exported to other countries. Despite of the challenges such as tariffs, labor and disease risks, the pork industry in US is still growing with around 66,000 sows in 2019. Also, developments by the major pork producers in the country is likely to grow the pork production industry. For instance, in 2017, 123-year-old Clemens Food Group partnered with 12 independent hog farmers to establish a new packing plant in Michigan. Thus, growing pork production industry is likely to favor market growth. In terms of genetic material, the animal genetics market is segmented into semen, and embryo. The embryo segment held the largest share of the market in 2019. In terms of service, the animal genetics market is segmented into DNA typing, genetic trait tests, genetic disease tests, and others.The DNA typing segment held the largest share of the market in 2019.

Animal Genetics Market: Competition Landscape and Key Developments

Neogen Corporation, Genus, Groupe Grimaud, Topigs Norsvin, Zoetis Services Llc, Hendrix Genetics Bv, Envigo, Vetgen, Animal Genetics Inc, Alta Genetics Inc. and among others are among the key companies operating in the animal genetics market. These players are focusing on the expansion and diversification of their market presence and the acquisition of a new customer base, thereby tapping prevailing business opportunities.

Order a Copy of Animal Genetics Market Shares, Strategies and Forecasts 2021-2028 Research Report athttps://www.theinsightpartners.com/buy/TIPRE00003517/

Browse Related Reports and Get Sample copy

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us:

If you have any queries about this report or if you would like further information, please contact us:

Contact Person:Sameer JoshiE-mail: [emailprotected]Phone:+1-646-491-9876Press Release: https://www.theinsightpartners.com/pr/animal-genetics-market More Research:https://www.einpresswire.com/newsroom/the_insight_partners/

SOURCE The Insight Partners

Go here to read the rest:

Animal Genetics Market Worth ($7705.23 Mn by 2027) by (6.3% CAGR) with Impact of Coronavirus Outbreak and Global Analysis & Forecast by The...

The plenary session of the Cuban Academy of Sciences today – SmallCapNews.co.uk

Havana November 27 A full Today, the regular session of the Cuban Academy of Sciences (ACC) will meet in person and in practice at the headquarters of the Information Technology and Advanced Remote Services Company (CITMATEL).

The deliberations will take place by video conference in four rooms prepared for academics from the provinces of Havana and Mayabeque, Doctor of Physical and Mathematical Sciences, Liliam Alvarez Diaz, Secretary of the Foundation, told CNA.

He explained that those belonging to the provincial branches will participate in the online discussions in each of the delegations of the Ministry of Science, Technology and Environment (CITMA).

According to its programme, one of the issues to be brought into academic consideration concerns the overall programs corresponding to the National Economic and Social Development Plan 2030.

The other will consist of the accountability of the ACC, by its chair, Luis Velzquez Perez, MD, a second-tier specialist in physiology.

The Cuban Academy of Sciences expanded its advisory job last May, when 420 scientific figures included it in its most recent internal election.

The latter is held every six years, and the academic body currently consists of those elected for the period 2018-2024, with a total of 183 full members and Merit 100; The honorable 44-year-old and the 31-year-old reporter to exercise their advisory role.

CITMATEL is one of the four national entities with High Technology status, characterized by demonstrating extensive R&D and innovation activity, as well as production and marketing of high value-added products and services, with an emphasis on exports.

The same is done by the Centers for Genetic Engineering and Biotechnology, Molecular Immunology (in the province of Havana) and the National Biopreparados (in Mayabeque). (Lino Lupine Perez)

Creator. Devoted pop culture specialist. Certified web fanatic. Unapologetic coffee lover.

Read the original post:

The plenary session of the Cuban Academy of Sciences today - SmallCapNews.co.uk

How Dr. Fauci and Other Officials Withheld Information on China’s Coronavirus Experiments – Newsweek

For half a year, Anthony Fauci, the nation's top infectious-disease official, and Kentucky senator and physician Rand Paul have been locked in a battle over whether the National Institutes of Health funded dangerous "gain of function" research at the Wuhan Institute of Virology (WIV) and whether that research could have played a role in the pandemic. Against Senator Paul's aggressive questioning over three separate hearings, Dr. Fauci adamantly denied the charge. "The NIH has not ever and does not now fund gain-of-function research in the Wuhan Institute of Virology," he said in their first fracas on May 11, a position he has steadfastly maintained.

Recently, however, a tranche of documents surfaced that complicate Dr. Fauci's denials. The documents, obtained by Freedom of Information Act requests, show that the NIH was funding research at the Wuhan lab that involved manipulating coronaviruses in ways that could have made them more transmissible and deadly to humanswork that arguably fits the definition of gain-of-function. The documents establish that top NIH officials were concerned that the work may have crossed a line the U.S. government had drawn against funding such risky research. The funding came from the NIH's National Institute of Allergy and Infectious Diseases (NIAID), which Dr. Fauci heads.

The resistance among Dr. Fauci and other NIH officials to be forthcoming with information that could inform the debate over the origins of COVID-19 illustrates the old Watergate-era saw that the coverup is often worse than the crime. There's no evidence that the experiments in question had any direct bearing on the pandemic. In the past, Dr. Fauci has made strong arguments for why this type of research, albeit risky, was necessary to prevent future pandemics, and he could have done so again. But the NIH has dragged its feet over FOIA requests on the matter, handing over documents only after The Intercept took the agency to court.

The apparent eagerness to conceal the documents has only raised suspicions about the controversial research and put the NIH on the defensive. Fauci told ABC, "neither I nor Dr. Francis Collins, the director of the NIH, lied or misled about what we've done." The episode is a self-inflicted wound that has further eroded trust in the nation's public health officials at a time when that trust is most important.

While Dr. Fauci takes the political heat, the revelations center on another figure in this drama: Peter Daszak, president of the private research firm EcoHealth Alliance, which received the $3 million NIH grant for coronavirus research and subcontracted the gain-of-function experiments to the Wuhan lab. The activities of Daszak and EcoHealth before the pandemic and during it show a startling lack of transparency about their work with coronaviruses and raise questions about what more there may be to learn.

From the start, Daszak has worked vigorously to discredit any notion that the pandemic could have been the result of a lab accident. When the media was first grappling with the basics of the situation, Daszak organized a letter in the prestigious medical journal The Lancet from 27 scientists, to "strongly condemn conspiracy theories suggesting that COVID-19 does not have a natural origin," and got himself appointed to the WHO team investigating COVID origins, where he successfully argued that there was no need to look into the WIV's archives.

What Daszak didn't reveal at the time was that the WIV had been using the NIH grant money to genetically engineer dozens of novel coronaviruses discovered in bat samples, and that he knew it was entirely possible that one of those samples had contained SARS-CoV-2 and had infected a researcher, as he conceded to the journal Science in a November 17 interview: "Of course it's possiblethings have happened in the past."

The NIH fought for more than a year to keep details about the EcoHealth grant under wraps. The 528 pages of proposals, conditions, emails, and progress reports revealed that EcoHealth had funded experiments at the WIV that were considerably riskier than the ones previously disclosed.

The trouble began in May 2016, when EcoHealth informed the NIH that it wanted to conduct a series of new experiments during the third year of its five-year grant. One proposed producing "chimeras" made from one SARS-like virus and the spike proteins (which the virus uses to infiltrate animal cells) of others, and testing them in "humanized" mice, which had been genetically engineered to have human-like receptors in their lungs, making them better stand-ins for people. When such novel viruses are created, there is always a risk they will turn out to be dangerous pathogens in their own right.

Another risky experiment involved the MERS virus. Although MERS is lethalit kills 35 percent of those who catch itit's not highly transmissible, which is partly why it has claimed fewer than 900 lives so far. EcoHealth wanted to graft the spikes of other related coronaviruses onto MERS to see how that changed its abilities.

Both experiments seemed to cross the gain-of-function line. NIH program officers said as much, sending Daszak a letter asking him to explain why he thought they didn't.

In his reply, Daszak argued that because the new spikes being added to the chimeras were more distantly related to SARS and MERS than their original spikes, he didn't anticipate any enhanced pathogenicity or infectiousness. That was a key distinction that arguably made them exempt from the NIH's prohibition on gain-of-function experiments. But, of course, one never knows; as a precaution, he offered that if any of the chimeric viruses began to grow 10 times better than the natural viruses, which would suggest enhanced fitness, EcoHealth would immediately stop all experiments, inform the NIH program officers, and together they'd figure out what to do next.

The NIH accepted Daszak's terms, inserting his suggestions into the grant conditions. Scientists at WIV conducted the experiments in 2018. To their surprise, the SARS-like chimeras quickly grew 10,000 times better than the natural virus, flourishing in the lab's humanized mice and making them sicker than the original. They had the hallmarks of very dangerous pathogens.

WIV and EcoHealth did not stop the experiment as required. Nor did they let the NIH know what was going on. The results were buried in figure 35 of EcoHealth's year-four progress report, delivered in April 2018.

Did the NIH call Peter Daszak in to explain himself? It did not. There are no signs in the released documents that the NIH even noticed the alarming results. In fact, NIH signaled its enthusiasm for the project by granting EcoHealth a $7.5 million, five-year renewal in 2019. (The Trump administration suspended the grant in 2020, when EcoHealth's relationship with the WIV came under scrutiny.)

In a letter to Congress on October 20, the NIH's Principal Deputy Director, Lawrence Tabak, acknowledged the screwup, but he placed the blame on EcoHealth's door, citing its duty to immediately report the enhanced growth that had occurred: "EcoHealth failed to report this finding right away, as was required by the terms of the grant." In a follow-up interview with the Washington Post, NIH Director Francis Collins was more blunt: "They messed up here. There's going to be some consequences for EcoHealth." So far, the NIH has not elaborated on what those consequences might be.

As damning as the NIH grant documents are, they pale in comparison to another EcoHealth grant proposal leaked to the online investigative group DRASTIC in September. In that 2018 proposal to the Defense Advanced Research Projects Agency, a Pentagon research arm, EcoHealth sketched an elaborate plan to discover what it would take to turn a garden-variety coronavirus into a pandemic pathogen. They proposed widely sampling Chinese bats in search of new SARS-related viruses, grafting the spike proteins from those viruses onto other viruses they had in the lab to create a suite of chimeras, then, through genetic engineering, introducing mutations into those chimeras and testing them in humanized mice.

One piece of the proposal was especially Strangelovian. For years, scientists had known that adding a special type of "cleavage site" to the spike could supercharge a virus's transmissibility. Although many viruses in nature have such sites, neither SARS nor any of its cousins do. EcoHealth proposed incorporating human-optimized cleavage sites into the SARS-like viruses it discovered and testing their infectiousness. Such a cleavage site, of course, is exactly what makes SARS-CoV-2 wildly more infectious than its kin. That detail was the reason some scientists initially suspected SARS-CoV-2 might have been engineered in a lab. And while there's no proof that EcoHealth or the WIV ever actively experimented with cleavage sitesEcoHealth says that "the research was never conducted"the proposal makes it clear that they were considering taking that step as early as 2018.

DARPA rejected the proposal, listing among its shortcomings the failures to address the risks of gain-of-function research and the lack of discussion of ethical, legal, and social issues. It was a levelheaded assessment. What's remarkable is that much of the same work that crossed a line for the Department of Defense was embraced by the National Institutes of Health.

The NIH and EcoHealth have asserted that none of the engineered viruses created with the NIH grant could have become SARS-CoV-2. On that, everyone agreesthe viruses are too distantly related. But the detailed recipe in the DARPA application is a blueprint for doing just that with a more closely related virus.

In September, scientists from France's Pasteur Institute announced the discovery of just such a virusSARS-CoV-2's closest known relativein a bat cave in Laos. Although still too distant from SARS-CoV-2 to have been the direct progenitor, and lacking the all-important cleavage site, it was a kissing cousin.

The discovery was hailed by some scientists as evidence that SARS-CoV-2 must have had a natural origin. But the plot turned in November, when another trove of NIH documentsreleased in response to a FOIA request by the White Coat Waste Projectbrought the evidence trail right to EcoHealth's doorstep.

In 2017, EcoHealth had informed the NIH that it would be shifting its focus to Laos and other countries in Southeast Asia, where the wildlife trade was more active, relying on local partner organizations to do the sample collecting and to send the samples to the WIV for their ongoing work. EcoHealth told Newsweek that it did not directly undertake or fund any of the sampling in Laos. "Any samples or results from Laos are based on WIV's work, funded through other mechanisms," says a company spokesman.

Regardless of who paid for the collecting portion of the project, it's clear that for years, a large number of bat samples from the region that harbors viruses similar to SARS-CoV-2 were sent to the WIV. In other words, EcoHealth's team was in the right place at the right time to have found things very close to SARS-CoV-2 and to have sent them to Wuhan. Because there's a lag of several years between when samples are collected and when experiments involving those viruses are published, the most recent papers from EcoHealth and the WIV date to 2015. The identity of the viruses found between 2016 and 2019 are known only to the two organizations, neither of which has been willing to share that information with the world.

A lack of evidence proves nothing, but neither does it put EcoHealth's or the WIV's actions in the early days of the pandemic in a good light. Why choose not to share valuable information on SARS-like coronaviruses with the world? Why not explain your projects and proposals and give scientists access to the unpublished virus sequences in your databases?

For whatever reason, they chose crisis-management mode instead. The WIV went into lockdown. Databases were taken offline. Daszak launched his preemptive campaign to prevent anyone from looking behind the curtain. And EcoHealth and the NIH tried hard to keep the details of their collaboration private.

Congressional inquiries focusing on Dr. Fauci and the NIH's decisions to fund unnecessarily risky research by a lab in Wuhan are probably forthcoming if, as appears increasingly likely, Republicans take control of Congress after the 2022 midterms. While it's important to understand how the NIH came to use such poor judgment in its dealings with EcoHealth Alliance, that won't tell us much about the WIV's research in the months leading up to the pandemic, especially since China is not likely to open its books. Answers are more likely to lie in the records of EcoHealth Alliance. Republicans and Democrats alike should be eager to find them.

Read the rest here:

How Dr. Fauci and Other Officials Withheld Information on China's Coronavirus Experiments - Newsweek

Career options in Food Technology – The Hindu

With land and water being limited resources, agriculture tends to face restrictions when it comes to food production. Therefore Biotechnology is used to enhance both production and the nutritional quality. Food Technology, which involved Biotechnology and Food Plant Engineering, is a scientific stream that deals with the conversion of raw edible agricultural produce into processed edible and innovative food products.

Techniques like genetic engineering, cloning and selective cultivation help increase the quantity of raw food material. The sensory acceptability of fruits and vegetables can also be enhanced. In the fermented food sector, probiotics, enzymes and single-cell proteins can be identified and developed. Food Technology can also help in sectors like cleaning, hygiene maintenance, smart packaging and shelf life of food.

Food Plant engineering includes processing methods, preservation by drying, low temperature or heat treatment. Food Process Engineering covers the design and process of equipment construction and the types of equipment used to package food, maintenance of food storage area, automation and use of robotics for facilitation of food workers.

A B.Tech in Food Technology has foundation courses like Chemistry, Physics, Engineering Design, Heat and Mass Transfer, Refrigeration and Air Conditioning, and Maths along with specialised courses about cereals, pulses, meat, poultry and fish processing, milk and milk product, bakery and confectionery, food chemistry, additives, food quality assurance, food microbiology, food safety and hygiene, and fruit and vegetable processing.

With the consumption of value-added and processed foods increasing, the food industry has expanded. New innovative techniques, scientific procedures, and new processing equipment have led to products with higher shelf life and specific foods are being developed for every age group. The work of a food processor begins after the harvest of crops. The quality of raw material, how it is transported and stored, pre-processing and final processing, packaging, storage and marketing, taste, and shelf life all come into this.

Food Technology is a promising sector that offers a sustainable and secure career with competitive earnings. Students opting for this field learn about basic processing methods and principles of processing, sources of raw food materials, post-harvest processing, transportation and storage of raw food and processed food products. They also learn about extracting ingredients, additives and the combinations to prepare a specific product apart from testing for quality and safety.

Apart from the government and the private sector, one can also become an entrepreneur. Job roles range from lab analyst, food processing operator, machinery inspection, food handler, research scientists, organic chemists, food inspector, managers and accountants. Hospitals, restaurants, food processing companies, catering services, food research labs, retailers, wholesalers, packaging industry and government bodies like FSSAI and FCI and warehouses are all areas to look for jobs.

The writer is the Dean, UPES School of Health Sciences, UPES University

See the article here:

Career options in Food Technology - The Hindu

How imaging is revolutionising biology – ScienceBlog.com – ScienceBlog.com

For the launch of the Year of Biology, the neurobiologist Daniel Choquet explains how progress in imaging has contributed to the current explosion of knowledge in the life sciences.

Is it fair to say that advances in imaging technology have brought about a new era in the life sciences?Daniel Choquet:Absolutely. Imaging is part of a series of revolutionary methods that are rapidly expanding knowledge in biology. I like quoting a remark by the South African biologist Sydney Brenner: Progress in science depends on new technologies, new discoveries, and new ideas, probably in that order. This is especially true in biology, for seeing new things enables us to raise fresh questions. Advanced imaging technologies have helped increase our exploration capacities.

What are the milestones of this imaging revolution?D. C.:Imaging has a long history, as the first microscopes go all the way back to the late sixteenth century. But this new revolution can be dated to the 1980s with the use in biology of fluorescent proteins, which can label molecules and thereby help study the mechanisms and processes at work in cells. Another milestone was the development of confocal microscopy and multiphoton microscopy, which provide three-dimensional images of tissue samples. Another key moment was the emergence, beginning in 2006, of super-resolution microscopes which can generate images of objects smaller than 250 nanometres, in both living and functioning tissue.

What objects and processes do these new technologies make possible?D. C.:I will use my favourite cells, neurons, as an example. The cell body of a neuron is approximately 20 microns. It is therefore within reach of conventional microscopes, which are limited by diffraction to a resolution of approximately a quarter micron. The discovery that the brain is not a gelatinous mass, and instead consists of individual cells, was actually made in the late nineteenth century by the Spanish neuroscientist Ramn y Cajal.

A synapse, or the connection between two neurons, typically measures one micron, which is close to the limits of conventional microscopy. It therefore cannot provide high-precision measurement or decode their complex organisation. With a resolution of one hundredth of a micron, super-resolution microscopy can observe not only synapses in action, but also the individual proteins behind a nervous signal.

These technologies enable us to study the dynamics at play when neurons are communicating. For example, my team has shown that synaptic receptors are not fixed to the membrane, but are instead constantly moving about.

Electron microscopy has also seen spectacular advances. What does this mean for the life sciences?D. C.:Electron microscopy has always been important for biology. It enabled the first visualisation of viruses, although the role of this technology has often been underestimated. From the 1980s, electron cryomicroscopy brought about another revolution, namely the ability to study the structure of proteins in 3D with a resolution on the order of the atom. Whats more, it makes it possible to see the different conformations adopted by these proteins, thereby helping us elucidate the functioning of these molecular machines while they are performing their task.

Another recent development involves imaging techniques for studying processes at the level of entire organs or living animals. What do they enable you to do?D. C.:This is a very important point, and here we are on the other side of the spectrum of cryomicroscopy. Thanks to labelling techniques and the miniaturisation of microscopes, we can obtain imaging of an entire animal while it is in action.

For example, we can install a microscope weighing a few grams on a rats head, and let it interact with its congeners or move through a labyrinth. This shows which neurons and regions of the brain are activated during a particular activity. It has already yielded important discoveries, such as the functioning of space and place cells, the neurons that enable us to remember specific locations, and to return to them at a later time.

These technologies show which cells are activated when an animal discovers or revisits an environment.

In other words, you can see memory as it is forming.D. C.:Precisely, this is the brain in action. This research can also be used for other organs, such as the spleen and the thymus gland. We can study organs affected by various diseases, and identify differences as compared with normal functioning. This research can also be coupled with genetic engineering in animals.

So new imaging technologies give you access to all scales. How do you coordinate this information?D. C.:This is a challenge of the future: how can we produce knowledge using a continuum of technologies that allows us to go from the atom to the human, from the angstrom to the metre? In an ideal world, we would be able to describe an entire human being at the molecular scale. This may be possible at some point, but today it is the stuff of science fiction. What we can do now is correlate the different scales of observation. Take for example a mouse performing a task. I discover that a specific part of the brain is active, and that a particular neuron in that region is communicating with its neighbours. I can collect a tissue sample and observe this neuron using super-resolution microscopy in order to see which synapses are active, and how they behave. I can then freeze these synapses and examine them with an electron microscope to study the 3D structure of membrane proteins, and to see how this structure changes when the neuron is activated. By overlapping correlation on different scales, we can move across scales and understand, for instance, which changes in protein conformation are connected to which behaviours in the animal.

What effect do these new technologies have on our approach to diseases, such as Alzheimers and Parkinsons?D. C.:Absolutely fascinating things are underway. In particular, there is a new method that combines imaging and transcriptomics, the study of all genes expressed in a cell or tissue. This enables us to study why certain individuals are severely affected by neurodegenerative diseases while others are not. Today we can image these differences between healthy and sick individuals, something that will be decisive in developing therapies. This is a step towards personalised medicine.

We are still in the midst of the Covid-19 pandemic. Can these imaging technologies contribute to the fight against infectious diseases?D. C.:They can indeed. First, it is thanks to electron microscopy that we know what the virus looks like. If we only had its genetic sequence, we would be half blind. For instance, we would not be aware of the importance of the Spike protein, which becomes quite obvious when we see it at the tip of SARS-CoV-2 spikes. Imaging also shows us the parts of the protein that medicine or neutralising antibodies should target in order to block it. Another example is research on Covid-19 symptoms. To study them we must know which tissues are infected, with imaging being decisive in this effort.

Supercomputers, artificial intelligence, learning algorithms How can computing power and analysis be combined with imaging to understand the living world?D. C.:We are in the midst of a boom. Artificial intelligence is invading our everyday lives without us knowing, and biology is no exception. It is indispensable if we want to study numerous parameters on multiple scales. The quantity of information produced is way beyond the grasp of the human brain: without computational resources, it would be impossible to analyse these petabytes of information. A particularly useful application involves teaching artificial neural networks to recognise protruding shapes. This is used widely in cryomicroscopy, as thousands of images are needed to determine the three-dimensional structure of proteins.

In your opinion, what will be the next technological revolution in imaging?D. C.:If I knew, I would have invested already! I think multi-scale analyses will increase. In situ imaging to study organs while they are functioning will become ever more important. Finally, there will be progress in the automation, robotisation, and miniaturisation of microscopes. These could eventually be small enough to enter the body and observe certain organs. What I expect from these advances is a better understanding of living things, and the development of personalised medicine. I think new therapies adapted to each genetic heritage will emerge. Concerning the brain, I think imaging will help with early detection of neurodegenerative diseases, as well as the development of treatments for disorders such as autism.

Original post:

How imaging is revolutionising biology - ScienceBlog.com - ScienceBlog.com

Novavax to Participate in Evercore ISI’s 4th Annual HealthCONx Virtual Conference – PRNewswire

GAITHERSBURG, Md., Nov. 23, 2021 /PRNewswire/ --Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it will participate in Evercore ISI's 4th Annual HealthCONx Virtual Conference. Novavax' recombinant nanoparticle protein-based COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion.

Conference Details:

Fireside Chat

Date:

Thursday, December 2, 2021

Time:

9:15 9:35 a.m. Eastern Time (ET)

Moderator:

Josh Schimmer

Novavax participants:

Gregory M. Glenn, M.D., President, Research and Development and John J. Trizzino, Executive Vice President, Chief Commercial Officer and Chief Business Officer

Conference

Event:

Investor meetings

Date:

Thursday, December 2, 2021

A replay of the recorded fireside session will be available through the events page of the Company's website at ir.novavax.com for 90 days.

About NovavaxNovavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform harnesses the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. NVX-CoV2373, the company's COVID-19 vaccine, received Emergency Use Authorization in Indonesia and the Philippines and has been submitted for regulatory authorization in multiple markets globally. NanoFlu, the company's quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults. Novavax is currently evaluating a COVID-NanoFluTMcombination vaccine in a Phase 1/2 clinical trial, which combines the company's NVX-CoV2373 and NanoFluTM vaccine candidates. These vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.

For more information, visit http://www.novavax.com and connect with us on Twitter and LinkedIn.

Contacts:

InvestorsNovavax, Inc. Erika Schultz | 240-268-2022[emailprotected]

Solebury TroutAlexandra Roy | 617-221-9197[emailprotected]

MediaAlison Chartan | 240-720-7804Laura Keenan Lindsey | 202-709-7521 [emailprotected]

SOURCE Novavax, Inc.

Go here to read the rest:

Novavax to Participate in Evercore ISI's 4th Annual HealthCONx Virtual Conference - PRNewswire

This Is the Best Sci-Fi Movie of All Time – 24/7 Wall St.

Special Report

November 28, 2021 12:00 pm

No one is quite sure what the earliest works of science fiction are. Of course, it depends on definitions. One of the often noted precursor works is Jonathan Swifts Gullivers Travels, released in 1726, while Mary Shelleys Frankenstein, released in 1818, is perhaps the most famous pre-20th century work of science fiction.

Frankenstein has become part of the pantheon of older science fiction characters, which include Dracula, who first appeared in 1897 in Bram Stokers book of the same name. These stories and characters also appear in many science fiction films, including some of the best. But the best science fiction movie of all time is Alien (1979). (These are the 50 greatest heroes in the movies.)

To determine the best sci-fi movie of all time, 24/7 Tempo developed an index using average ratings on IMDb and a combination of audience scores and Tomatometer scores on Rotten Tomatoes as of October 2021. Great sci-fi doesnt just entertain. It criticizes the present and warns us (or excites us) about the future. It makes us think. It provides us with a sense of wonder. But mostly it can be pretty darn entertaining. (These are the 100 greatest movies ever made.)

Alien is a great example of science fiction that makes us think. Despite director Ridley Scotts assertion that his only intention with the movie was terror, according to Slate, Alien spawned many academic analyses, remaining relevant to this day.

The movie (spoilers ahead) tells the story of the crew of a commercial space tug named Nostromo, who are awoken from stasis on their way back to Earth in order to investigate a transmission coming from a nearby alien moon. All hell breaks loose after they land, and before long theres a horrifying rogue alien brilliantly designed by H.R. Giger terrorizing them (and bursting forth from poor John Hurts chest).

With its fast-paced, edge-of-your-seat storyline, Alien was a smash hit that captured audiences and inspired countless films and TV shows, and it launched a franchise thats still going strong.

Click here to see the 50 best sci-fi movies of all time

Methodology

To determine the best sci-fi movie of all time, 24/7 Tempo developed an index using average ratings on Internet Movie Database, an online movie database owned by Amazon, and a combination of audience scores and Tomatometer scores on Rotten Tomatoes, an online movie and TV review aggregator, as of October 2021. All ratings were weighted equally. Only movies with at least 15,000 audience votes on either IMDb or Rotten Tomatoes were considered. The countless Star Wars movies and superhero fantasies based on Marvel Comics or DC Comics characters were excluded from consideration. Directorial credits and cast information comes from IMDb.

The rest is here:

This Is the Best Sci-Fi Movie of All Time - 24/7 Wall St.

AstraZeneca: Five innovations from Cambridge’s new 1bn headquarters – ITV News

During the pandemic, Cambridge-based AstraZeneca became a household name for its role in creating a Covid-19 vaccination alongside scientists from Oxford University.

But the biopharmaceutical company has also led the way in several other cutting-edge scientific innovations.

The company has more than 76,000 employees worldwide, and its work focuses on developing prescription medication in areas such as oncology, rare diseases and the respiratory system.

Much of that work will now be driven from its new 1bn Cambridge headquarters - so here are five ways that the research centre is leading the way.

1. 'Heart-in-a-jar'

In collaboration with biotech company Novoheart, scientists at AZ are re-creating miniature organs to help them better understand things like the human heart.

A mini beating heart is created using the company's "3D human ventricular cardiac organoid chamber" - better known as the heart-in-a-jar. Scientists hope it will help them understand the characteristics of heart failure better, and therefore get treatments to patients quicker.

2. Functional genomics

Scientists are finding new ways of understanding how human genes work. Through what they call 'functional geonomics', AZ is testing the function of a given gene in a relevant disease model. And that, they say, will help them understand the complex relationship between our DNA and disease.

3. Using 'living medicines' to find cancer cells hiding in the body

Scientist are looking at regenerating tissues and organs by extracting a patient's own cells or using cells which have been expanded in the lab or enhanced through genetic engineering.

Those cells are then used to produce "living medicines" and are administered to the patient - known as cell therapy. It builds on research that analyses the way serious diseases affect different parts of the body.

The aim is to find ways to target and arm these living medicines to locate and destroy cancer cells that hide in the body, including even the hardest-to-treat solid tumours.

4. Cancer 'warheads'

AZ scientists say they are "re-defining" cancer by replacing chemotherapy with targeted, personalised therapies. While chemo kills cancer cells, it also impacts healthy ones too.

AZ is working on a tailored treatment it calls "the warhead". It is designed to kill cells and - unlike chemotherapy - scientists can now achieve precise cancer cell killing by attaching the warhead to an antibody, that provides cancer cell selectivity for example by targeting a protein that is highly expressed in breast cancer.

5. Clinical trials of the future

AstraZeneca is hoping to change the way pharmaceutical companies conduct clinical research, encouraging a more "holistic and human-centred" type of care.

Scientists want to do this by altering the design of clinical trials themselves in a way that gives patients the best experience possible.

Read more about science innovation in the Anglia region here:

Go here to see the original:

AstraZeneca: Five innovations from Cambridge's new 1bn headquarters - ITV News

Cyberpunk 2077 Is Having Its First Good Day – Kotaku

A visual allegory.Screenshot: CD Projekt

Poor old Cyberpunk 2077. Is a phrase I never thought Id think. But here we are, just a couple of weeks away from its first year on sale (!), and I do find myself feeling odd twinges. Because goodness me, its rather popular on Steam today.

Hovering in the top half of Steams top 10 top sellers, CD Projekts beleaguered game seems to be finding new love with its current half price sale. Down to $30, rather than the incredibly optimistic $60 its laughably maintained for almost 12 months, people are jumping to get it. And, you know what, fair enough really. Because at this point the game has received literally thousands of bug fixes, patches, patches to fix previous patches, removed wetness, added even wetterness, and on the PC at least, is a functioning, enormous RPG.

On console, thats still a whole other matter. In a year that has seen CD Projekt get hacked, their source code stolen and auctioned online, they tried to bury the severity of that hack under the noise of E3, while also being taken off sale by Sony for six months, and having the extent of the crunch their developers were put under made very visible. Which perhaps could have been better received if the promised next-gen versions of the game for PS5 and XBS had appeared when promised. Which of course they didnt. And still havent.

But todaytoday theyre having a good day. As VCG reported, CDP president Adam Kiciski got all giddy and told Polish newspaper Rzeczpospolita, We believe that in the long run Cyberpunk 2077 will be perceived as a very good game, and like our other titles, it will sell for years.

Meanwhile, Cyberpunks quest director, PaweSasko, rushed to Twitter in child-like joy at seeing the game get not-terrible reviews on Steam. In fact, boosted by the current sale, the game is registering Very Positive.

G/O Media may get a commission

Noting that these reviews have arrived in the last few days, Sasko adds, You cant imagine what it means to me. Sniff.

He later added, Over 15K very positive reviews in the last days, while both #Cyberpunk2077 and #TheWitcher3 are on the global list of Steam top sellers, concluding, Thank you so much!

Forbes caught the game at the very top of Steams list earlier, although at the time of writing its being pipped by, er, Farming Simulator 22.

Eventually someones going to tap them all on the shoulder and remind them theyve got to get the game working for consoles at some point, and the sadness will all rush back in. But lets let them have this one.

Visit link:

Cyberpunk 2077 Is Having Its First Good Day - Kotaku

Cyberpunk 2077 Patch 1.4: Game Dev Highlights Issues With Ai That Need Fixing in Update – GiveMeSport

Cyberpunk 2077 is a game that has been rife with issues and glitches ever since it was released on public sale, but now an indie game developer has given his knowledge and expertise on some of the AI problems in the CD Projekt Red title.

While improvements have already been made to the game over the past year with patching, there are still glaring issues with the AAA title overall.

CD Projekt Red does seem determined to fix these issues and fully realise the title that fans have hoped for from the very beginning.

Writing on the r/CyberpunkGame subreddit u/Alamoa20, an indie game dev with experience, highlighted some of the issues across the AI in the game, and what CDPR will hopefully be looking at to rectify them.

They said: When I look at Night City's Civilians, they're obviously not finite state machines. They have behavioural trees and a path. You can see them walking, stopping at a vending machine and getting a drink, sitting down at a bench, leaning on a railing, looking at their phone, taking a smoke, a drink, a snack.

The problem is that it's incomplete. There's no "loopback", so to speak. They keep walking till they despawn or till they turn around and walk back.

Read More: Cyberpunk 2077 Patch 1.4 Update: Release Date, Roadmap, Patch Notes and Everything We Know So Far

The Redditor would also point out the issues with the Police AI in the game, which fans have been commenting on since the games initial release.

Police AI is no different. Them spawning behind you is so jarringly obvious, that it is insane for me to think devs saw this and thought it was okay.

They needed and wanted a system, but the one they were working on was likely NOT going to be ready by release date, so they had to work around it. A simple spawn out of the player's zone of sight. Inside a building, out in the desert.

No testing was done. Just a placeholder illusion to say Okay, the system is there, at least. It's a very watered down iteration.

Were expecting that the next update for the game will be introduced in early 2022, with CDPR having noted this year that theyre looking to release the Next-Gen versions of the game on PS5 and Xbox Series X/S in the new year.

Read More: Cyberpunk 2077 Patch 1.4 Update: Fans React to Potential Multiplayer Release

Enter the November Giveaway to win a Nintendo Switch with Mario Kart 8 Deluxe and FIFA 22 Legacy Edition!

You can find all of the latest Cyberpunk 2077 News and everything Gaming related right here at GiveMeSport.

See the original post here:

Cyberpunk 2077 Patch 1.4: Game Dev Highlights Issues With Ai That Need Fixing in Update - GiveMeSport

The Home Depot’s secret to creating the brightest tree with Christmas lights – Real Homes

There's nothing more festive than putting up the Christmas tree and going totally overboard with the decorations.

Once you've got your best artificial Christmas tree out, baubles at the ready, the next hurdle is untangling the lights. The Home Depot has shared a golden rule that will make your tree shine extra bright this year.

(Image credit: Cox & Cox)

Sarah Fishburne is the Director of Trend and Design at The Home Depot. Working in Atlanta, she leads a team of interior designers. When it comes to Christmas lights, she has a 'go big or go home' philosophy.

'For live trees and shrubs, use 100 mini lights or 50 C7 lights for every vertical foot,' she advises.

(Image credit: Cox & Cox)

More sparse-looking, asymmetrical trees have proven popular this year, with people embracing slimline trees with a branch out of place.On such trees, Sarah says can use half that number of lights, so you'll only need 50 for every vertical foot.

However, if you want the brightest tree in your neighbourhood, the key is to double that number. 'Depending on your preferences, you may want a brighter tree,' Sarah says. 'In which case you can double the number of recommended lights,' she says.

(Image credit: Cox & Cox)

We knew it, more is always more when it comes to Christmas decorating ideas.

With Black Friday home deals and Cyber Monday offers ongoing, you may just bag yourself some additional string lights at a great price. The Home Depot Christmas lights that have been most popular this year are the Holiday 300-Light Clear Incandescent Mini Lights and the Set of 100 Warm White LED Lights on Green Wire.

You might want to add some festive Christmas lighting to other areas of your home besides the tree to help set the mood. Wherever you're hanging your lights, Sarah recommends starting with 'at least 60 feet' of string lights.

The same goes for exterior Christmas lights, and if you have the time and patience, you can measure your eaves and awnings to determine the exact length of string lights you need.

Turning on the tree lights each morning is one of the joys of the festive season, so make sure you have plenty for that extra Christmas magic.

See the rest here:

The Home Depot's secret to creating the brightest tree with Christmas lights - Real Homes

Have a stress-free flight this holiday season – MSU Denver Newsroom

November 23, 2021

By Mark Cox

The prospect of festive flying is looking anything but jolly this year.

The Transportation Security Administration said that it expected to screen an estimated 20 million people over the Thanksgiving travel period, which began last week. And airports are bracing for near pre-pandemic levels of holiday travel next month as well.

As air travel has ramped up, so have the headaches: expensive fares, canceled flights, airport crowds, sardine-packed planes and disruptive passengers.

Dont worry, though: Jeff Price, Metropolitan State University of Denver Aviation professor, has some expert advice to help you avoid any nightmare trips.

Book early, if possible

Its the golden rule of booking flights: Prices will go up the longer you wait. There definitely is an optimal window when airfares are typically at their lowest, Price said, and thats usually around three months out. But there may still be some good deals out there for the holiday season since airlines sometimes add late flights.

Get to the airport early

The security-checkpoint lines can change, ebb and flow considerably at DIA, which recommends arriving in the terminal at least two hours in advance of your flight. During busy periods, its worth arriving earlier than usual since you may need to navigate around the airport to find your line entrance, especially if youre a member of Clear or TSA PreCheck. Check the DIA website for all the latest parking, airport and flight information and to subscribe for updates.

Remember to mask up

If youre heading to an airport, dont forget your mask. The federal government requires all passengers, regardless of vaccination status, to wear their mask at all times with the exception of when they are eating or taking a drink, Price said.

Id suggest buying a mask that is comfortable to wear, easy to breathe in and doesnt get too hot, said Price, who has travelled by air twice in the past two weeks. Its a worthy investment if you want a more comfortable flight.

Stay Covid-safe and sanitize

A crowded airport is like a giant petri dish filled with germs. To help protect against the spread of Covid-19, the Transportation Security Administration is allowing travelers to bring up to 12 ounces of hand sanitizer, plus alcohol or anti-bacterial wipes, in their carry-on bags.

Check your flight, then check it again

When youre traveling during the holidays, one thing you can rely on is that you cant really rely on anything. During holiday season, Price said, there are always lots of flight changes, delays and, unfortunately, cancellations especially if there is bad weather.

He recommends downloading a flight app so you can regularly check for delays or changes to your itinerary.

Many airline apps, such as FlightAware and FlightRadar, now enable you to track the real-time status of your flight, which is incredibly useful, Price said.

Flying internationally? Check for travel restrictions

Travel rules have been eclectic and fluid lately, so international travelers should carefully check the latest requirements for all stages of their journey.

The Department of State website is a good place to find clear guidance on restrictions regarding international locations, Price said. And Id also recommend checking websites in the actual country youre visiting for additional information, restrictions or rules.

Listen to airport staff

The TSA has warned that its going to be a busy holiday season. And as passenger numbers start ramping up again, airport security staff have a simple request: Listen to them because they can help.

Travelers should pay attention to the guidance TSA officers provide at checkpoints, TSA Administrator David Pekoske said. They could be directing you to a shorter line or guiding you around someone who is moving slowly. And they may give you advice that will lessen the likelihood that youll need a pat-down.

Unruly passengers

Pandemic-era flying has seen an unprecedented rise in air-rage incidents. More than 85% of flight attendants have had to deal with unruly passengers this year. And Prices advice is stark: Dont be one of those people.

Interference with a crew member is a federal offense, he said. Unruly passengers may find themselves under criminal prosecution and ultimately have to pay hundreds of thousands of dollars in fines. Its really not worth it.

If youre on a flight and someone starts acting up, however, then its up to you whether to intervene.

There could be repercussions, of course, just like if you tried to stop a fight on the street, Price said. But in most cases, passengers who assist crew members have not been arrested for trying to help.

Excerpt from:

Have a stress-free flight this holiday season - MSU Denver Newsroom

If you’re on the fence | Opinion | dailyitem.com – Sunbury Daily Item

Ive been in orthopedic practice in this community for approaching 35 years. Id like to believe Ive either helped, or at least tried my very best to help, as many of my patients as I possibly could. I appreciate the fact that Ive made many of my patients more than that and were also now friends. Friends who trust me to care for them, their spouses, their children, and their parents.

Ive always tried to practice medicine by the golden rule of doing for your patients as if they were your own family.

So I ask you, those that are not vaccinated, or havent received your boosters, to please do so. There are many untruths about the COVID vaccine that exist.

As in anything that happens in health care there is whats called a Risk Benefit Ratio. There are risks in receiving a treatment and there are risks in not receiving a treatment. For those of you who are undecided as to get vaccinated, as your friend, your caregiver, someone that you may have trusted to provide you spinal care, injury care, to care for your families, I beg you, I beseech you all, to please set aside any fears, political standings, the inconvenience and get vaccinated.

At our beloved community hospital alone weve had 135 deaths and sadly the number continues to rise unnecessarily.

Many unvaccinated people have exposed not only themselves but also their families to this potentially lethal virus and the outcome has been deadly.

Our hospital staff has been overwhelmed with the sadness and sense of helplessness that occurs when trying to save someone who is dying from COVID. The human cost to this can be crushing.

Whenever I see a veteran wearing a military hat, I always go out of my way to thank them for their service to our country. As a final note, consider doing the same when you see a health care provider these days. It makes a difference to them I know.

I accept the fact that some will never get vaccinated, but if youre on the fence, and you trust me, please do it, for yourselves, for your family, for our country.

Dr. Paul S. Lin,

Lewisburg

Read the original here:

If you're on the fence | Opinion | dailyitem.com - Sunbury Daily Item

All of the Jason Bateman movies and shows on Netflix – Netflix Life

Ozark is one of the most popular series on Netflix, and the fourth and final season will release in January 2022. The first seven episodes will come out first, with the remaining seven to follow later. In the meantime, you can check out other movies and shows on the streamer starring Ozarks leading man Jason Bateman.

Bateman is anactor, director and producer who started his acting career in the 1980s when he starred in Little House on the Prairie.He would go on to star in other 80s shows such asSilver Spoons and The Hogan Family.

Since that time, Bateman has become a seasoned actor as well as a director. He has directed Bad Words, The Family Fang and Ozark, and starred in Juno, The Switch, The Break-up, Horrible Bosses and its sequel.

Be sure to check out the movies starring Bateman that are available to watch on Netflix.

This series sees Bateman as the patriarch of the Byrde family, Marty. The title is the location he transplants his family to when he becomes embroiled in a huge money-laundering scheme.

The Byrdes meet many unsavory people who they eventually get into business with to maintain the laundering of so much money. The first three seasons have been outstanding, and the fourth and final is likely to be even more dynamic.

Arrested Development

Bateman playedMichael Bluthon theFox/NetflixsitcomArrested Development from 2003 to 2019, a role for which he would earn a Golden Globe and Satellite Award.

This series follows the Bluths, a once-wealthy and always dysfunctional family. Michael is forced to keep the crew on track after his father is arrested for shifty accounting practices in the family-owned business.

In this superhero comedy, Bateman stars with Melissa McCarthy,Octavia Spencer,Bobby Cannavale,Pom Klementieff,Taylor Mosby and Melissa Leo. This film is written and directed by Ben Falcone, McCarthys husband, marking their fifth collaboration.

Thunder Force is a Netflix original that follows two childhood friends who have discovered a way to become superheroes.

Bateman portrays a villain called The Crab who doesnt have superpowers but has crab legs, complete with claws where his arms should be. There is an interesting backstory to how he acquired his crab claws.

The political thriller State of Play is based on a British series of the same name.

Russell Crowe plays journalist Cal McAffrey, who digs into the story of a suspicious death of a Congressman Stephen Collins (Ben Affleck) mistress.

Dominic Foy, played by Bateman, is a PR executive at a subsidiary of PointCorp, aprivate defense contractor being investigated by Collins for its controversial operations involving mercenaries.

It is a thrilling movie with a great cast that also includesRachel McAdams, Robin Wright Penn, Jeff Daniels and Helen Mirren.

Starsky & Hutch is an adaptation of the 1970s TV series of the same name. Ben Stiller plays David Starsky andOwen Wilson plays Ken Hutch Hutchinson in the comedy action movie.

This movie is a prequel to the TV series and explains how Starsky and Hutch became partners. They are undercover cops in Bay City, California, who bust drug criminals with the assistance of Huggy Bear (Snoop Dogg), an underworld boss.

Bateman plays Kevin Jutsum, right-hand man to drug kingpin Reese Feldman (Vince Vaughn). They develop a new type of cocaine that is untraceable by scent or taste.

The comedy The Sweetest Thing isdirected byRoger Kumbleand written byNancy Pimental, who based the characters on herself and friendKate Walsh (fromGreys Anatomy).

Best friends Christina (Cameron Diaz) and Courtney (Christina Applegate) abide by their golden rule when dating: Avoid searching for Mr. Right and focus on Mr. Right Now. One night Christina meets Peter (Thomas Jane) and hes nowhere to be found the next day, so the girls head out on a road trip to find him. Like any road trip, this one becomes wild with many hilarious moments along the way.

Bateman plays Peters womanizing brother Roger.

Is your favorite Jason Bateman movie or show on Netflix?

See the rest here:

All of the Jason Bateman movies and shows on Netflix - Netflix Life

LFCC’s Fauquier campus will add building dedicated to skilled trades education – Fauquier Times

Construction of a new 8,000-square-foot building dedicated to the skilled trades on the Fauquier campus of Lord Fairfax Community College is expected to begin in February and be open for classes in fall 2022.

An LFCC press release said that the building is being made possible through a gift of 60 acres adjacent to campus from Fauquier County to theLFCCEducational Foundation. The college has been leasing space for trades instruction at Vint Hill, but that site is not ideal for those needs, the release said, and the lease expires in 2022.

With the new trades building, the college will be able to offer trades classes for the first time in Fauquier, and even begin a new carpentry program. Electrical, HVAC, plumbing and heavy equipment operator programs will be held in the new structure.

Providing career training and apprenticeships in the trades requires a custom-designed facility we need flexible labs for hands-on learning, hard floors, high ceilings, state-of-the-art ventilation systems, multiple outlets and drop cords to accommodate the industrial and commercial training equipment, said Jeanian Clark, vice president of Workforce Solutions and Continuing Education, in the press release.

Thats why this new building is such exciting news. And it couldnt come at a better time. With the states investment in the G3, FastForward and Re-Employing Virginians initiatives, enrolling in skilled-trades programs and high-demand career pathways has never been more affordable for students. Our area businesses and industries need our trades graduates, Clark said.

In addition to expanding trade offerings, the new facility will allow the college to explore partnerships with Fauquier County and Rappahannock County schools for potential new ventures, such as a trades academy.

The expansion of trades programs on the Fauquier campus is good news for the home construction industry, saidLFCCFoundation Board Member Joel Barkman in the press release. He is founder and president/CEO of Golden Rule Builders in Catlett.

By investing in the infrastructure to develop the next generation of building trade professionals,LFCCis a valuable partner in addressing the skilled labor shortage. Im proud to support the college, he said.

The foundation, which will own the building and lease it to the college, has established the Building the Future Fund with a fundraising goal of $1.5 million. According to the press release, the money raised will go toward fully equipping the site; bringing in experienced instructors; offering scholarships, and expanding instruction to more fields within career and technical education.

There are naming opportunities for the building itself, as well as spaces inside, according to the press release.

For more information or to donate to the Building the Future Fund, anyone interested may contact Tami OBrien, development officer, at 540-351-1046 ortobrien@lfcc.edu.

Go here to see the original:

LFCC's Fauquier campus will add building dedicated to skilled trades education - Fauquier Times

Forum, Nov. 26: Thanks to everyone who supports nonprofits – Valley News

Published: 11/25/2021 10:00:27 PM

Modified: 11/28/2021 10:00:03 AM

At this time of year we give thanks, and we thank by giving. Here in the Upper Valley are numerous local organizations that receive support of work and money from those who are able.

Organizations often print an annual list of donors to recognize the support from larger donors and individuals with more limited means. It heartens me that many volunteers and donors recognize the importance nonprofits have in nurturing our community. This year, I am thankful that my neighbors participate in helping organizations such as Red Logan Dental Clinic, the Upper Valley Land Trust and the Lebanon Opera House.

Nov. 30 is this years Giving Tuesday. This day is a way to balance the materialism celebrated on Black Friday with care for the world and those in need. Thank you to all who support others and work to preserve and protect the Earth, which is our home.

INGRID CURTIS

Etna

Thank you, Valley News, for highlighting folks shopping locally this year (Shoppers thinking outside the box, Nov. 22).

We are fortunate to live among so many talented craftspeople. Shopping locally directly benefits the community by supporting local businesses and crafters. It also benefits our community in a less direct way when the local craft fair is associated with a fundraiser for social services. As one example, the Bugbee Senior Center is hosting a craft fair Dec. 3 and 4 at the center in White River Junction.

Revenue from the event supports the center, which provides a variety of services to Upper Valley seniors. This past year we served more than 25,000 meals through Meals on Wheels and daily lunch at the center. We provided local seniors with fitness and health programs, including fall prevention. Seniors who came back to the center after the isolation of COVID-19 are so grateful. Now they are back to their card games, crafts, trips, educational activities and, of course, bingo. Please keep local craft fairs in mind when shopping for your loved ones, some of whom might even frequent the Bugbee Senior Center.

SUSAN MANLEY

Wilder

The writer is volunteer and activity coordinator at the Bugbee Senior Center.

This holiday season, please add the Hanover Garden Club to your list of organizations doing things differently! In addition to our traditional in-person sale, we are offering items via an online order format: https://form.jotform.com/212916992795170. (Payment is made at the time of pick up or delivery.)

The clubs sale is one of the last of the season, so our products are fresh for holiday gatherings. They include tabletop boxwood trees, mixed green centerpieces, English cracker/poppers (very fun!) and gift boxes of cookies. All items are made by club members. The traditional holiday sale will take place at the RW Black Community Center, 48 Lebanon St., Hanover, on Dec. 11, from 9 a.m. to noon. The above-mentioned items will be available, along with the clubs Gardeners Nook, Attic Treasures and jewelry tables. While shopping, enjoy some free coffee, tea and homemade treats.

All proceeds from this sale are used to plant the 13 gardens around the town of Hanover. Thank you for keeping the gardens alive for all to enjoy.

BETSY EATON and MARY WAUGH

Hanover

The writers are co-chairs of the Hanover Garden Club holiday sale.

Suzanne Lupiens Perspectives column in the Sunday Valley News touched my heart (Weve forgotten how much we really need each other, Nov. 21). I agree with her when she says people dont have a choice about getting the vaccine, and I too believe that the actions of individuals affect us all.

But take heart, because people are still giving and concerned about their neighbors. Two years ago, my husband was struck with an illness that put him in the hospital for a week and left him unable to perform the many chores that we do on our farm in Grantham.

One of these chores is throwing in wood for my woodstove. Yes, I still cook on a woodstove, and we put in our own wood, just like we did in Cornish when I was a child. Hearing of our situation, neighbors, friends and relatives all came on a Sunday afternoon, some from many miles away, to throw wood into our cellar.

Yes, the ancient golden rule of the countryside was being observed at our farm in Grantham that Sunday, and it was not just elderly but young and old who came to help. The only thing that could have made that day more wonderful would have been a platter of Bernice Johnsons wonderful doughnuts, which I have been lucky enough to have shared with her.

CINDY TOWLE

Grantham

See the article here:

Forum, Nov. 26: Thanks to everyone who supports nonprofits - Valley News

Premier League golden goose isnt cooked governing bodies will sit on English football review – The Offside Rule

Fans cant trust that the report recommendations will be swiftly implemented while top-flight clubs are profiting from a broken system, writes Laura Lawrence.

Less than 12 hours after the government commissioned review into English football was released, Aston Villas chief executive Christian Purslow said the following on the BBC Radio 4 Today show:

The Premier League has always really been the source of funding for the rest of football and the danger here is of course, as you said, killing the golden goose if we over-regulate a highly successful financial and commercial operation.

Nothing to see here. Just the free-market economy working so well for the few and not the many. The Premier League sucked up all the money long ago so clubs further down the pyramid had no choice but to rely on begrudged handouts.

Of course, the golden goose doesnt want government intervention. Whats in it for them when the system has been weighted to their advantage?

Former Sports Minister and chair of the review panel Tracey Crouch, believes the answer lies in a new independent regulator. While the governing bodies (The Football Association, Premier League and English Football League) acknowledge changes need to be made they believe they can solve the problems between themselves. I give a hearty laugh to that one. Especially at the FA who have been as useful as a chocolate fireguard as English football goes up in flames.

The report laid out 47 recommendations to stop the industry from lurching from crisis to crisis. The report itself is sound. Recommendations include changes to the Owners and Directors Tests and assessments of the flow of money through the leagues.

The protection of clubs from free-market economics has also been addressed in the review. The heritage of clubs should be taken into account and guarded. The recommendation is to introduce into legislation a golden share for supporters so they would have a say over major plans such as moving grounds. These protections are needed but the report doesnt address how situations like Newcastle Uniteds ownership would be addressed.

Villas CEO doesnt believe that a government appointee is the right person to take on the issues within football. We killed the Super League in 48 hours. Itll take her (Crouch) 48 weeks to appoint someone.

While I agree with the sentiment that it may move at a glacial government pace, if members of the Premier League hadnt attempted the Super League coup in the first place this intervention wouldnt be as high on the government agenda.

If it was anyone other than this government, I might trust that the findings of this report would be implemented but they have just voted for the free-market privateers to sit on NHS primary care trust panels. Footballs governing bodies will sit on this report for as long as possible. Dont expect quick changes. The few are making money from the broken system. That will sound familiar to this government.

Follow Laura on Twitter@YICETOR

Like Loading...

Related

Read this article:

Premier League golden goose isnt cooked governing bodies will sit on English football review - The Offside Rule

Community Voices: What is the correct stance? – The Bakersfield Californian

On Dec. 1, the Supreme Court will hear arguments in Dobbs v. Jackson Womens Health Organization, a case in which the state of Mississippi is seeking to ban abortions after 15 weeks of pregnancy. Pro-choice advocates see it as a challenge to Roe v. Wade, which permits abortions so long as the fetus is not yet viable, which amounts to considerably more than 15 weeks.

Which side is correct, and why? Each side has its strengths and each its weaknesses. Is there a compromise?

Pro-choice advocates point to the influential Turnaway Study, which followed 1,132 women seeking an abortion at 30 abortion clinics in 22 states over a 12-year period. Half got the abortion they sought, while half were turned away. The Study was designed to compare the long-term effects on women in the two groups. Writing about the Study in The New Yorker, Margaret Talbot found that there were no long-term differencesin depression, anxiety, PTSD, self-esteem, life satisfaction, drug abuse, or alcohol abuse among the two groups. She underscored the finding that only 5 percent of the aborters regretted their decision five years later and that there was little evidence to support the claim by pro-lifers that a large percentage of aborters are wracked with guilt later in life. She concluded that the evidence was welcome news for anyone who supports reproductive justice. She also pointed out, ingenuously, that the vast majority of women whod been denied abortion were glad five years later that they hadnt been able to get one welcome evidence that a 5-year-old child will almost always capture the heart of a mother.

The Turnaway Study makes a strong case for the advantages of getting an abortion, but it doesnt address the sticky moral issue of ending the life of a future human being, much less an already existing one.

The strength of pro-life, by contrast, is that it tackles this issue head on. This is not to say that its position is correct, only that it doesnt shirk the moral question. According to the United States Conference of Catholic Bishops, the union of sperm and egg at conception produces a new living being that is distinct from both mother and father. Modern genetics demonstrated that this individual is, at the outset, distinctively human, with the inherent and active potential to mature into a human fetus, infant, child and adult. Catholic teaching declares that the presence of an immaterial soul created by God and placed in its fleshly receptacle gives it an inherent dignity possessed uniquely by a human person. It rejects an old theory that the receptacle must reach fetal status before it can be ensouled.

The weakness of the Catholic position is that it cannot demonstrate that an immaterial soul is implanted in this new being or that it even exists. At best it can claim, according to its pro-choice opponents, that the fetus is on a trajectory toward becoming a person, and that to claim more is a matter of faith that is not shared by everyone. Thus, for pro-choice, an abortion does not constitute murder, and the well-being of the mother is justifiably the first consideration, in fact the only consideration that is relevant.

Ancillary factors might come into play. The decision to deny human life to a fetus that is well on the way to becoming a person cannot be easy. Pro-choice parents, female and male alike, have only to ask what would have happened to them if their parents had chosen to abort them. The Golden Rule, we would hope, would weigh heavily in their decision. Couples with money and support who choose to abort because they hadnt planned on a child and dont want to be bothered with one dont usually earn our admiration.

On the other hand, there might be good reason for those inclined not to abort to question their resolve. Most of us can imagine circumstances we would dread being born into. Would we choose life if we knew our mother was on crack or lived in dire poverty with no father to help raise us? Heartless though it might sound, some of us can even say about people we know that it would have been better for them not to be born.

In the final analysis, is there a compromise position? Ultimately it would seem not: either the fetus is a person or it is not. If not, a person is not being killed. If so, a person is being killed, and we can justifiably call it murder. How can we decide?

President Biden, a Catholic, has made it clear that he personally cannot condone abortion but will not condemn those who do. He justifies his position by pointing out that as president of the nation he has no right to condemn those who disagree with him: he was elected to represent all, whatever their personal views. He feels justified in receiving Communion in his Church, and he has the Popes support. But what about Catholics who dont feel the burden of representing a large constituency? Should they think of pro-choice advocates as murderers?

On the other hand, should pro-choice advocates denounce pro-lifers as gullible, perhaps stupid victims of an unsupportable superstition required by their Church?

My answer is no to both questions. For me it is impossible to decide based on the evidence at hand. I would choose not to abort if an unwanted pregnancy showed up, but my decision would not be based on a certainty. I would bear in mind that what happens at conception is unknowable, and this uncertainty would keep me from condemning those who abort. I believe that a compassionate agnosticism is the correct position to take.

Of course, the Supreme Court will not have such a luxury. The justices will have to decide, and both sides will probably find a lot to dislike. Nevertheless, the rancor that divides the nation over this issue should find no place in our hearts. Whatever our view, we should remember that the other side has its reasons, and they should be respected.

Stafford Betty is professor emeritus of religious studies at Cal State Bakersfield.

See the rest here:

Community Voices: What is the correct stance? - The Bakersfield Californian